Literature DB >> 23026948

Transplantation: Sirolimus for secondary SCC prevention in renal transplantation.

Fabian Halleck, Klemens Budde.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23026948     DOI： 10.1038/nrneph.2012.216

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  9 in total

1.  Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.

Authors:  Josep M Campistol; Josette Eris; Rainer Oberbauer; Peter Friend; Brian Hutchison; José M Morales; Kerstin Claesson; Giovanni Stallone; Graeme Russ; Lionel Rostaing; Henri Kreis; James T Burke; Yves Brault; Joseph A Scarola; John F Neylan
Journal:  J Am Soc Nephrol       Date:  2006-02       Impact factor: 10.121

2.  Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer.

Authors:  S B Campbell; R Walker; S See Tai; Q Jiang; G R Russ
Journal:  Am J Transplant       Date:  2012-03-15       Impact factor: 8.086

3.  Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.

Authors:  Josefina Alberú; Michael D Pascoe; Josep M Campistol; Francesco P Schena; Maria Del Carmen Rial; Martin Polinsky; John F Neylan; Joan Korth-Bradley; Robert Goldberg-Alberts; Eric S Maller
Journal:  Transplantation       Date:  2011-08-15       Impact factor: 4.939

Review 4.  Sirolimus for calcineurin inhibitors in organ transplantation: contra.

Authors:  Paolo Cravedi; Piero Ruggenenti; Giuseppe Remuzzi
Journal:  Kidney Int       Date:  2010-08-11       Impact factor: 10.612

5.  Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial.

Authors:  R Salgo; J Gossmann; H Schöfer; H G Kachel; J Kuck; H Geiger; R Kaufmann; E H Scheuermann
Journal:  Am J Transplant       Date:  2010-02-01       Impact factor: 8.086

Review 6.  Skin cancer in organ transplant recipients--where do we stand today?

Authors:  C Ulrich; J Kanitakis; E Stockfleth; S Euvrard
Journal:  Am J Transplant       Date:  2008-09-08       Impact factor: 8.086

7.  Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.

Authors:  Timothy Mathew; Henri Kreis; Peter Friend
Journal:  Clin Transplant       Date:  2004-08       Impact factor: 2.863

8.  Sirolimus and secondary skin-cancer prevention in kidney transplantation.

Authors:  Sylvie Euvrard; Emmanuel Morelon; Lionel Rostaing; Eric Goffin; Anabelle Brocard; Isabelle Tromme; Nilufer Broeders; Veronique del Marmol; Valérie Chatelet; Anne Dompmartin; Michèle Kessler; Andreas L Serra; Günther F L Hofbauer; Claire Pouteil-Noble; Josep M Campistol; Jean Kanitakis; Adeline S Roux; Evelyne Decullier; Jacques Dantal
Journal:  N Engl J Med       Date:  2012-07-26       Impact factor: 91.245

Review 9.  An evaluation of sirolimus in renal transplantation.

Authors:  Fabian Halleck; Michael Duerr; Johannes Waiser; Lu Huber; Mareen Matz; Susanne Brakemeier; Lutz Liefeldt; Hans-Hellmut Neumayer; Klemens Budde
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-08-28       Impact factor: 4.481
  9 in total
  6 in total

Review 1.  Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.

Authors:  Daniel Fantus; Natasha M Rogers; Florian Grahammer; Tobias B Huber; Angus W Thomson
Journal:  Nat Rev Nephrol       Date:  2016-08-01       Impact factor: 28.314

Review 2.  Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data.

Authors:  Greg A Knoll; Madzouka B Kokolo; Ranjeeta Mallick; Andrew Beck; Chieny D Buenaventura; Robin Ducharme; Rashad Barsoum; Corrado Bernasconi; Tom D Blydt-Hansen; Henrik Ekberg; Claudia R Felipe; John Firth; Lorenzo Gallon; Marielle Gelens; Denis Glotz; Jan Gossmann; Markus Guba; Ahmed Ali Morsy; Rebekka Salgo; Earnst H Scheuermann; Helio Tedesco-Silva; Stefan Vitko; Christopher Watson; Dean A Fergusson
Journal:  BMJ       Date:  2014-11-24

3.  While reinforcing cell cycle arrest, rapamycin and Torins suppress senescence in UVA-irradiated fibroblasts.

Authors:  Olga V Leontieva; Mikhail V Blagosklonny
Journal:  Oncotarget       Date:  2017-05-11

Review 4.  From rapalogs to anti-aging formula.

Authors:  Mikhail V Blagosklonny
Journal:  Oncotarget       Date:  2017-05-30

5.  Cancer and mTOR inhibitors in kidney transplantation recipients.

Authors:  Chih-Chin Kao; Jia-Sin Liu; Yu-Kang Chang; Ming-Huang Lin; Yen-Chung Lin; Hsi-Hsien Chen; Wei-Chiao Chang; Chih-Cheng Hsu; Mai-Szu Wu
Journal:  PeerJ       Date:  2018-11-08       Impact factor: 2.984

6.  Primary small cell carcinoma after renal transplant: A case report.

Authors:  Xueli Wang; Fenghua Wang; Yumei Liang; Wen Chen
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.